Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PHILIP J MEASE

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1336218171
CMS profile
60322
Location
SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$297,223.79

356 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
UCB, Inc. $52,808.43 52
Lilly USA, LLC $50,412.80 25
ABBVIE INC. $37,304.06 45
Janssen Biotech, Inc. $31,336.14 25
Janssen Scientific Affairs, LLC $24,675.03 45
UCB SA $23,430.00 2
E.R. Squibb & Sons, L.L.C. $20,412.50 9
PFIZER INC. $13,877.78 18
Novartis Pharmaceuticals Corporation $9,233.20 65
Takeda Pharmaceuticals U.S.A., Inc. $7,502.64 15
SUN PHARMACEUTICAL INDUSTRIES INC. $7,491.78 4
GlaxoSmithKline, LLC. $6,888.27 4
Eli Lilly and Company $4,375.00 1
ARGENX US, INC. $2,500.00 1
Amgen Inc. $1,963.79 10
Merck Sharp & Dohme LLC $1,651.49 2
Genentech, Inc. $851.49 19
GENZYME CORPORATION $134.39 4
Biogen, Inc. $112.12 1
Alexion Pharmaceuticals, Inc. $77.25 1
AstraZeneca Pharmaceuticals LP $55.00 3
Genentech USA, Inc. $34.84 1
Octapharma USA, Inc. $28.04 1
TerSera Therapeutics LLC $25.48 1
KYOWA KIRIN, INC. $25.04 1
Fresenius Kabi USA, LLC $17.23 1

Page 3 of 8; records 101–150 of 356 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PHILIP J MEASE

NPI 1336218171 · CMS profile ID 60322

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 8; records 101–150 of 356 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336218171?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PHILIP J MEASE, NPI 1336218171, CMS profile ID 60322. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 356 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336218171?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). PHILIP J MEASE, NPI 1336218171, CMS profile ID 60322. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 356 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336218171?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
PHILIP J MEASE, NPI 1336218171, CMS profile ID 60322, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 8; records 101–150 of 356 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1336218171?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

356 matching records · $297,223.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 356 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 356.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $1,775.0010/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224476142 CMS
ABBVIE INC. $9.6610/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203062582 CMS
GENZYME CORPORATION $42.5010/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233197112 CMS
Lilly USA, LLC $330.5210/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186759383 CMS
Lilly USA, LLC $169.4810/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186780593 CMS
Lilly USA, LLC $169.4810/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186799701 CMS
Lilly USA, LLC $335.4610/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186831236 CMS
Lilly USA, LLC $571.8810/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186844091 CMS
Janssen Scientific Affairs, LLC $575.0010/10/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174205596 CMS
Novartis Pharmaceuticals Corporation $21.3110/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200597813 CMS
ABBVIE INC. $4,900.0010/06/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1203062580 CMS
ABBVIE INC. $9.1709/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203062578 CMS
Lilly USA, LLC $3,500.0009/23/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186774360 CMS
Lilly USA, LLC $3,075.0009/23/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186819362 CMS
Novartis Pharmaceuticals Corporation $3,200.0009/22/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200641030 CMS
Takeda Pharmaceuticals U.S.A., Inc. $31.1209/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223925379 CMS
Janssen Biotech, Inc. $149.9409/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175331211 CMS
Novartis Pharmaceuticals Corporation $49.7809/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200597809 CMS
Novartis Pharmaceuticals Corporation $21.4509/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200597811 CMS
Janssen Scientific Affairs, LLC $5,800.0009/15/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174205581 CMS
Janssen Biotech, Inc. $1,450.0009/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175327976 CMS
Janssen Biotech, Inc. $14.9609/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175325891 CMS
Novartis Pharmaceuticals Corporation $24.4809/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200597807 CMS
UCB, Inc. $3,195.0009/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1224476136 CMS
Genentech, Inc. $14.8509/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211567753 CMS
Lilly USA, LLC $139.1209/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186819366 CMS
Merck Sharp & Dohme LLC $134.4909/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238001196 CMS
Novartis Pharmaceuticals Corporation $105.1309/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200641032 CMS
Amgen Inc. $4.2009/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227116475 CMS
UCB, Inc. $82.2708/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224476132 CMS
UCB, Inc. $6,000.0008/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224476134 CMS
ABBVIE INC. $8.2908/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203062576 CMS
Novartis Pharmaceuticals Corporation $25.1808/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200597805 CMS
PFIZER INC. $1,300.0008/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1229061969 CMS
ABBVIE INC. $6.3608/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203062574 CMS
Lilly USA, LLC $8,312.5008/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186819360 CMS
ABBVIE INC. $33.5008/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203062572 CMS
Janssen Biotech, Inc. $1,450.0008/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175328369 CMS
E.R. Squibb & Sons, L.L.C. $4,062.5008/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1184796342 CMS
Amgen Inc. $31.9608/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228688162 CMS
ABBVIE INC. $31.4308/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203062570 CMS
Genentech, Inc. $14.8508/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211567748 CMS
Genentech, Inc. $266.7308/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211567783 CMS
Janssen Biotech, Inc. $5,075.0008/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175329029 CMS
Janssen Biotech, Inc. $1,450.0008/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175329222 CMS
ABBVIE INC. $9.2107/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203062568 CMS
ABBVIE INC. $3.7507/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203062564 CMS
ABBVIE INC. $35.5407/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203062566 CMS
Janssen Biotech, Inc. $7,975.0007/23/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175331290 CMS
GlaxoSmithKline, LLC. $19.2407/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190709177 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $467,672.55 560
PY2020 $358,355.43 263
PY2021 $296,727.43 289
PY2022 $291,777.52 339
PY2023 $225,369.94 293
PY2024 $200,182.53 280
PY2025 $297,223.79 356

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $22,060.23 4
PY2025 Principal investigator $813,204.11 31
PY2024 Recipient $15,735.75 10
PY2024 Principal investigator $564,403.48 19
PY2023 Recipient $10,000.00 8
PY2023 Principal investigator $271,522.65 36
PY2022 Recipient $59,879.00 39
PY2022 Principal investigator $147,121.27 32
PY2021 Recipient $74,031.06 44
PY2021 Principal investigator $339,422.91 70
PY2020 Recipient $59,649.40 69
PY2020 Principal investigator $395,626.16 86
PY2019 Recipient $56,628.80 33
PY2019 Principal investigator $417,345.94 113

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $780.00 12/31/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 2a, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases No dispute reported 06/30/2026 1246638302
Principal investigator 1 Janssen Research & Development, LLC $7,249.80 12/19/2025 Non-covered Recipient Entity
GROUP FOR RESEARCH AND ASSESSMENT O
Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA_) A Pilot Study No dispute reported 06/30/2026 1175349807
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 12/19/2025 Non-covered Recipient Entity
GROUP FOR RESEARCH AND ASSESSMENT O
Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA_) A Pilot Study No dispute reported 06/30/2026 1175349827
Principal investigator 1 Janssen Research & Development, LLC $3,466.00 12/18/2025 Non-covered Recipient Entity
GROUP FOR RESEARCH AND ASSESSMENT O
Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA_) A Pilot Study No dispute reported 06/30/2026 1175349820
Principal investigator 1 AstraZeneca Pharmaceuticals LP $61,950.08 12/10/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 1b 2 Study of AZD0120 a Chimeric Antigen Receptor Tcell CAR T Therapy Targeting CD19 and Bcell Maturation Antigen BCMA in Subjects with Refractory Systemic Lupus Erythematosus SLE No dispute reported 06/30/2026 1185542930
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,080.00 12/08/2025 Non-covered Recipient Entity
Bloodworks Northwest
A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, or Rheumatoid Arthritis (Breakfree-1) No dispute reported 06/30/2026 1235998596
Recipient SOBI, INC $1,050.00 12/01/2025 Covered Recipient Physician PAXIS/PAC601 No dispute reported 06/30/2026 1240177385
Principal investigator 1 Janssen Research & Development, LLC $32,500.00 11/17/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175430901
Principal investigator 1 Janssen Research & Development, LLC $6,685.00 10/27/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175430986
Principal investigator 1 Janssen Research & Development, LLC $8,348.00 10/17/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175430794
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,237.00 10/10/2025 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223269382
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,500.00 10/10/2025 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223269384
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,800.00 10/10/2025 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223269386
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 10/10/2025 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223269388
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,000.00 10/01/2025 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223269380
Principal investigator 1 Eli Lilly and Company $5,924.00 09/09/2025 Non-covered Recipient Entity
SEATTLE RHEUMATOLOGY ASSOCIATES
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187888254
Principal investigator 1 UCB SA $38,450.00 09/04/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246656705
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $859.66 08/26/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEXT CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE) No dispute reported 06/30/2026 1236000148
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 06/23/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175430422
Principal investigator 1 UCB SA $829.14 05/28/2025 Non-covered Recipient Entity
Seattle Rheumatology Associates
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246659531
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $51,368.52 05/13/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, or Rheumatoid Arthritis (Breakfree-1) No dispute reported 06/30/2026 1236000156
Principal investigator 1 Janssen Research & Development, LLC $2,557.00 05/12/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175430980
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $45,123.82 05/07/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment No dispute reported 06/30/2026 1236000150
Principal investigator 1 Janssen Research & Development, LLC $3,270.00 04/10/2025 Non-covered Recipient Entity
GROUP FOR RESEARCH AND ASSESSMENT O F PSORIASIS AND PSORIATIC ARTHRITIS
Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA_) A Pilot Study No dispute reported 06/30/2026 1175349799
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 04/10/2025 Non-covered Recipient Entity
GROUP FOR RESEARCH AND ASSESSMENT O F PSORIASIS AND PSORIATIC ARTHRITIS
Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA_) A Pilot Study No dispute reported 06/30/2026 1175349812
Recipient SOBI, INC $2,450.00 04/10/2025 Covered Recipient Physician PAC601 No dispute reported 06/30/2026 1240177383
Recipient PFIZER INC. $3,200.00 04/08/2025 Covered Recipient Physician TOFACITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770844
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,650.00 03/28/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) No dispute reported 06/30/2026 1236000152
Recipient Novartis Pharmaceuticals Corporation $15,360.23 03/05/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190293569
Principal investigator 1 Janssen Research & Development, LLC $5,791.00 02/20/2025 Covered Recipient Teaching Hospital
Swedish Issaquah
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175430500
Principal investigator 1 Amgen Inc. $6,247.31 01/30/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Active Psoriatic Arthritis No dispute reported 06/30/2026 1246638314
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $81,674.42 01/27/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, or Rheumatoid Arthritis (Breakfree-1) No dispute reported 06/30/2026 1236000154
Principal investigator 1 Celgene Corporation $33,250.00 01/24/2025 Non-covered Recipient Entity
Bloodworks Northwest
A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, or Rheumatoid Arthritis (Breakfree-1) No dispute reported 06/30/2026 1222305640
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $347,853.12 01/24/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, or Rheumatoid Arthritis (Breakfree-1) No dispute reported 06/30/2026 1236000158
Principal investigator 1 Amgen Inc. $7,158.24 01/21/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or ? 1 Conventional Synthetic DMARD No dispute reported 06/30/2026 1246638312